Actively Recruiting
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Led by Regeneron Pharmaceuticals · Updated on 2026-01-22
317
Participants Needed
42
Research Sites
631 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma * What side effects may happen from taking linvoseltamab together with another cancer treatment * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
CONDITIONS
Official Title
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Measurable multiple myeloma disease according to International Myeloma Working Group criteria
- Adequate kidney, blood, and liver function as defined in the protocol
- Life expectancy of at least 6 months
- Relapsed or refractory multiple myeloma with progression after at least 3 prior therapies, or at least 2 prior therapies with specific prior drug exposures or refractory status as detailed in cohort criteria
- Specific prior treatment and washout periods depending on cohort (e.g., anti-CD38 antibody, carfilzomib, lenalidomide, bortezomib, pomalidomide, isatuximab)
You will not qualify if you...
- Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (not myeloma-associated), Waldenström macroglobulinemia, or POEMS syndrome
- Known brain lesions or meningeal involvement from multiple myeloma
- Receiving systemic anti-myeloma therapy within 5 half-lives or 21 days before study drug
- History of allogeneic or autologous stem cell transplant as defined
- Prior treatment with BCMA-targeted T cell therapies (excluding antibody-drug conjugates)
- History of progressive multifocal leukoencephalopathy, neurodegenerative or CNS movement disorders, or seizures in past 12 months
- Live or attenuated vaccine within 28 days before study drug
- Cardiac ejection fraction below 40%
- Additional cohort-specific exclusions including peripheral neuropathy grade 2 or higher, malabsorption syndromes, prior immune therapies, autoimmune disease, organ transplants, and abnormal heart rhythm or drug interactions as detailed in protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 42 locations
1
Scripps Clinic Torrey Pines
La Jolla, California, United States, 92037
Actively Recruiting
2
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States, 30004
Actively Recruiting
3
Indiana University Health Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Actively Recruiting
4
Dana Farber/Harvard Cancer Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
5
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
6
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
7
Weill Cornell Medicine/New York Presbyterian Hospital
New York, New York, United States, 10021
Actively Recruiting
8
New York Presbyterian Hospital Columbia University Medical Center
New York, New York, United States, 10032
Actively Recruiting
9
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
10
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
11
The Ohio State University James Cancer Hospital
Columbus, Ohio, United States, 43210
Actively Recruiting
12
University of Texas Southwestern
Dallas, Texas, United States, 75390
Actively Recruiting
13
VA Puget Sound Health Care System
Seattle, Washington, United States, 98108
Actively Recruiting
14
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, New Aquitaine, France, 86021
Actively Recruiting
15
CHU de Lille - Rue Michel Polonovski
Lille, Nord, France, 59037
Suspended
16
Nantes University Hospital
Nantes, Pays de la Loire Region, France, 44093
Actively Recruiting
17
Centre Hospitalier Universitaire Angers
Angers, France, 49933
Actively Recruiting
18
CHU Montpellier - Departement D'Hematologie
Montpellier, France, 34295
Actively Recruiting
19
Saint Antoine Hospital
Paris, France, 75571
Actively Recruiting
20
Institut Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
21
Hospital Henri Mondor
Créteil, Île-de-France Region, France, 94000
Actively Recruiting
22
Saint Louis Hospital
Paris, Île-de-France Region, France, 75010
Actively Recruiting
23
Hopital Necker
Paris, Île-de-France Region, France, 75015
Actively Recruiting
24
Evangelismos General Hospital
Athens, Attica, Greece, 10676
Actively Recruiting
25
General Hospital of Athens Alexandra
Athens, Greece, 11528
Actively Recruiting
26
Sheba Medical Center
Ramat Gan, Central District, Israel, 5265601
Actively Recruiting
27
Rambam Health Care Campus
Haifa, Israel, 3109601
Actively Recruiting
28
Hadassah Medical Center
Jerusalem, Israel, 91120
Actively Recruiting
29
Hospital Clinico Universitario de Santiago
Santiago de Compostela, A Coruna, Spain, 15706
Actively Recruiting
30
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916
Actively Recruiting
31
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain, 39008
Actively Recruiting
32
Hospital Universitario Quiron Salud Madrid
Pozuelo de Alarcón, Madrid, Spain, 28223
Actively Recruiting
33
Clinica Universidad de Navarra
Pamplona, Navarre, Spain, 31008
Actively Recruiting
34
Hospital Universitario Vall d'Hebron
Barcelona, Spain, 08035
Actively Recruiting
35
Hospital Clinic de Barcelona
Barcelona, Spain, 08036
Actively Recruiting
36
Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
Barcelona, Spain, 08908
Actively Recruiting
37
Universitaru Hospital La Princesa
Madrid, Spain, 28006
Actively Recruiting
38
Clinica Universidad de Navarra - Madrid
Madrid, Spain, 28027
Actively Recruiting
39
Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
Madrid, Spain, 28034
Actively Recruiting
40
University Hospital and Research Institute
Madrid, Spain, 28041
Actively Recruiting
41
Hospital Universitario HM Sanchinarro
Madrid, Spain, 28050
Actively Recruiting
42
University Hospital of Salamanca
Salamanca, Spain, 37007
Actively Recruiting
Research Team
C
Clinical Trials Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
10
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here